Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis

Srdan Verstovsek; Ross L. Levine; Brady L. Stein

doi:10.1016/j.clml.2014.08.002

Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis

Srdan Verstovsek, Ross L. Levine, Brady L. Stein

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	e229
Journal	Clinical Lymphoma, Myeloma and Leukemia
Volume	14
Issue number	6
DOIs	https://doi.org/10.1016/j.clml.2014.08.002
State	Published - Dec 2014

Funding

Funding: This activity is supported by an educational grant from Incyte Corporation . Funding: This activity is supported by an educational grant from Incyte Corporation.Srdan Verstovsek, MD, PhD has research grants from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Cell Therapeutics, Inc.; Geron; Gilead Sciences, Inc.; lncyte Corporation; Infinity Pharmaceuticals, Inc.; Lilly Oncology; Novartis Pharmaceuticals Corporation; NS Pharma, Inc.; Promedior, Inc.; Roche; Seattle Genetics; YM Biosciences.Ross L. Levine, MD has a research grant from Incyte Corporation.

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clml.2014.08.002

Cite this

@article{498f9e703c3e4e7b8fbbcb8f7eed2956,

title = "Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis",

author = "Srdan Verstovsek and Levine, {Ross L.} and Stein, {Brady L.}",

note = "Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation . Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation.Srdan Verstovsek, MD, PhD has research grants from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Cell Therapeutics, Inc.; Geron; Gilead Sciences, Inc.; lncyte Corporation; Infinity Pharmaceuticals, Inc.; Lilly Oncology; Novartis Pharmaceuticals Corporation; NS Pharma, Inc.; Promedior, Inc.; Roche; Seattle Genetics; YM Biosciences.Ross L. Levine, MD has a research grant from Incyte Corporation.",

year = "2014",

month = dec,

doi = "10.1016/j.clml.2014.08.002",

language = "English (US)",

volume = "14",

pages = "e229",

journal = "Clinical Lymphoma, Myeloma and Leukemia",

issn = "2152-2650",

publisher = "Cancer Media Group",

number = "6",

}

TY - JOUR

T1 - Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis

AU - Verstovsek, Srdan

AU - Levine, Ross L.

AU - Stein, Brady L.

N1 - Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation . Funding Information: Funding: This activity is supported by an educational grant from Incyte Corporation.Srdan Verstovsek, MD, PhD has research grants from AstraZeneca; Bristol-Myers Squibb; Celgene Corporation; Cell Therapeutics, Inc.; Geron; Gilead Sciences, Inc.; lncyte Corporation; Infinity Pharmaceuticals, Inc.; Lilly Oncology; Novartis Pharmaceuticals Corporation; NS Pharma, Inc.; Promedior, Inc.; Roche; Seattle Genetics; YM Biosciences.Ross L. Levine, MD has a research grant from Incyte Corporation.

PY - 2014/12

Y1 - 2014/12

UR - http://www.scopus.com/inward/record.url?scp=85097174384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85097174384&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2014.08.002

DO - 10.1016/j.clml.2014.08.002

M3 - Comment/debate

AN - SCOPUS:85097174384

SN - 2152-2650

VL - 14

SP - e229

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

IS - 6

ER -

Applying Janus Kinase 2 (JAK2) Inhibitors to the Treatment of Chronic Myelofibrosis

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this